A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Sponsor
Bristol-Myers Squibb
Study ID
NCT06952465
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    As per product label
  • Any biologic treatment for psoriasis — BIOLOGICAL
    According to the product label

Study Details

The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting

Key Dates

Start date
Jan 24, 2025
Status verified
Apr 2025
Primary completion
Nov 30, 2031
Completion
Nov 30, 2031

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants receiving deucravacitinib treatment
  • Arm: Cohort 2
    Participants receiving biologics treatment for psoriasis

Primary Outcome Measure

Participant baseline demographics [ Time Frame: Baseline ]

Related Studies